CHALLENGE STOCK VALIDATION

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 到目前为止，还没有商业疫苗可以预防丝状病毒的感染。我们项目的总体目标是开发免疫学工具来评估疫苗制剂的免疫反应。在接种疫苗前两周，将采集血液以建立免疫基线。在接种当天，动物将用5种腺病毒疫苗或空腺病毒载体对照进行免疫。在接种后2、3、4、5、7、9、11、13周，经股静脉穿刺采血，进行ELISAT和ELISPOT检测。此外，在第13周，动物将被实施安乐死，以分离脾细胞并储存血清以供将来分析。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. To date, no commercial vaccine is available to protect against infection with filoviruses. The overall aim of our project is to develop immunological tools to evaluate immune response to vaccine formulations. Two weeks prior to vaccination, blood will be collected to establish an immunological baseline. On day of vaccination, animals will be immunized with one of 5 adenovirus based vaccines or an empty adenovector control. At week 2, 3, 4, 5, 7, 9, 11, 13 post vaccination, blood will be collected via femoral venipuncture for ELISA and ELISPOT development. In addition, at week 13, animals will be euthanized for isolation of splenocytes and storage of serum for future analysis.